Bibliography
- James EL : Vaccination against cancer may result from discovery by British medical experts. The Globe, No. 23,566, 17 July (1925).
- Gerritsen W , Van Den Eertwegh AJ, De Gruijl T et al.: A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patient with hormone-refractory prostate cancer (mHRPC). Proc. Am. Soc. Clin. Oncol.24 , 100 (2006) (Abstract 2500).
- Small EJ , FratesiO, ReeseDMet al.: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.J. Clin. Oncol.18 , 3894–3903 (2000).
- Small EJ , SchellhammerPF, HiganoCSet al.: Placebo-controlled Phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.J. Clin. Oncol.24 , 3089–3094 (2006).
- Slovin SF , RagupathiG, MusselliCet al.: Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N- acetylgalactosamine-o-serine/threonine (Tn) conjugate vaccine.J. Clin. Oncol.21 , 4292–4298 (2003).
- Slovin SF , RagupathiG, FernandezCet al.: A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 or QS-21.Vaccine23 , 3114–3122 (2005).
- Slovin SF , RagupathiG, FernandezCet al.: Thomsen–Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.Cancer Immunol. Immunother.54 , 694–702 (2005).
- Scher HI , HellerG: Clinical states in prostate cancer: toward a dynamic model of disease progression.Urology55 , 323–327 (2000).
- Gulley JL , ArlenPM, MadanRAet al.: Immunologic and prognostic factors associated with overall survival employing a poxviral-based G vaccine in metastatic castrate-resistant prostate cancer.Cancer Immunol. Immunother.1 , 27–29 (2009).
- Arlen PM , SkarupaL, PazdueMet al.: Clinical safety of a viral vector based prostate cancer vaccine strategy.J. Urol.1178 , 1515–1520 (2007).
- Kantoff PW , SchuetzT, BlumensteinBAet al.: Overall survival (OS) analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).J. Clin. Oncol.27 , (Suppl. 15) (2009) (Abstract 5013).
- Terasawa H , TsangKY, GulleyJ, ArlenP, SchlomJ: Identification and characterization of a human agonist cytotoxic T-lymphocytes epitope of human prostate-specific antigen.Clin. Cancer Res.18 , 41–53 (2002).
- Gulley J , ChenAP, DahutWet al.: Phase I study of a vaccine using recombinant vaccinia virus expressing G (rV-G) in patients with metastatic androgen-independent prostate cancer.Prostate153 , 109–117 (2002).
- Schellhammer PF , HiganoC, BergerERet al.; for the IMPACT Study Investigators: A randomized, double-blind, placebo-controlled multi-center, Phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). Presented at: American Urological Association Annual Meeting. Chicago, IL, USA, 25–30 April 2009.
- Halabi S , SmallEJ, KantoffFWet al.: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.J. Clin. Oncol.121 , 1232–1237 (2003).